Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.58 USD | +2.49% | +2.49% | -21.95% |
08/04 | Replimune Group Provides Interim Results for Skin Cancer Therapy | MT |
26/03 | Replimune Group, Inc. Announces Management Changes | CI |
Sales 2024 * | - | Sales 2025 * | 6.12M 511M | Capitalization | 394M 32.88B |
---|---|---|---|---|---|
Net income 2024 * | -213M -17.77B | Net income 2025 * | -226M -18.86B | EV / Sales 2024 * | - |
Net cash position 2024 * | 259M 21.63B | Net cash position 2025 * | 167M 13.93B | EV / Sales 2025 * | 37.1 x |
P/E ratio 2024 * |
-2.03
x | P/E ratio 2025 * |
-2.23
x | Employees | 284 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.2% |
Latest transcript on Replimune Group, Inc.
1 day | +2.49% | ||
1 week | +2.49% | ||
Current month | -19.46% | ||
1 month | -14.88% | ||
3 months | -18.87% | ||
6 months | -53.79% | ||
Current year | -21.95% |
Managers | Title | Age | Since |
---|---|---|---|
Sushil Patel
CEO | Chief Executive Officer | 53 | 03/21/03 |
Colin Love
FOU | Founder | 66 | 01/15/01 |
Founder | 52 | 01/15/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paolo Pucci
BRD | Director/Board Member | 63 | 01/20/01 |
Joseph Slattery
BRD | Director/Board Member | 59 | 01/17/01 |
Robert Coffin
FOU | Founder | 59 | 01/15/01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.09% | 0 M€ | 0.00% | - | |
0.05% | 0 M€ | 0.00% | - | |
0.03% | 773 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
30/24/30 | 6.58 | +2.49% | 480 317 |
26/24/26 | 6.42 | +4.39% | 603,791 |
25/24/25 | 6.15 | -2.84% | 783,453 |
24/24/24 | 6.33 | -1.40% | 631,812 |
23/24/23 | 6.42 | 0.00% | 1,157,333 |
Delayed Quote Nasdaq, April 30, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.95% | 394M | |
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |
- Stock Market
- Equities
- REPL Stock